Discovery of novel SPAK inhibitors that block WNK kinase signaling to cation chloride transporters

Eriko Kikuchi, Takayasu Mori, Moko Zeniya, Kiyoshi Isobe, Mari Ishigami-Yuasa, Shinya Fujii, Hiroyuki Kagechika, Tomoaki Ishihara, Tohru Mizushima, Sei Sasaki, Eisei Sohara, Tatemitsu Rai, Shinichi Uchida

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Upon activation by with-no-lysine kinases, STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) phosphorylates and activates SLC12A transporters such as the Na+-Cl2 cotransporter (NCC) and Na+-K+-2Cl2 cotransporter type 1 (NKCC1) and type 2 (NKCC2); these transporters have important roles in regulating BP throughNaCl reabsorption and vasoconstriction. SPAK knockoutmice are viable and display hypotension with decreased activity (phosphorylation) of NCC and NKCC1 in the kidneys and aorta, respectively. Therefore, agents that inhibit SPAK activity could be a new class of antihypertensive drugs with dual actions (i.e., NaCl diuresis and vasodilation). In this study, we developed a new ELISA-based screening system to find novel SPAK inhibitors and screened .20,000 small-molecule compounds. Furthermore, we used a drug repositioning strategy to identify existing drugs that inhibit SPAK activity. As a result, we discovered one small-molecule compound (Stock 1S-14279) and an antiparasitic agent (Closantel) that inhibited SPAK-regulated phosphorylation and activationofNCCandNKCC1in vitro and inmice. Notably, these compounds had structural similarity and inhibited SPAK in an ATP-insensitivemanner.Wepropose that the two compounds found in this study may have great potential as novel antihypertensive drugs.

Original languageEnglish
Pages (from-to)1525-1536
Number of pages12
JournalJournal of the American Society of Nephrology
Volume26
Issue number7
DOIs
Publication statusPublished - 2015 Jul 1

Fingerprint

Protein Kinase Inhibitors
Proline
Alanine
Cations
Chlorides
Protein Kinases
Phosphotransferases
Antihypertensive Agents
Sodium-Potassium-Chloride Symporters
Drug Repositioning
Phosphorylation
Antiparasitic Agents
Diuresis
Vasoconstriction
Vasodilation
Hypotension
Lysine
Aorta
Adenosine Triphosphate
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Nephrology

Cite this

Kikuchi, E., Mori, T., Zeniya, M., Isobe, K., Ishigami-Yuasa, M., Fujii, S., ... Uchida, S. (2015). Discovery of novel SPAK inhibitors that block WNK kinase signaling to cation chloride transporters. Journal of the American Society of Nephrology, 26(7), 1525-1536. https://doi.org/10.1681/ASN.2014060560

Discovery of novel SPAK inhibitors that block WNK kinase signaling to cation chloride transporters. / Kikuchi, Eriko; Mori, Takayasu; Zeniya, Moko; Isobe, Kiyoshi; Ishigami-Yuasa, Mari; Fujii, Shinya; Kagechika, Hiroyuki; Ishihara, Tomoaki; Mizushima, Tohru; Sasaki, Sei; Sohara, Eisei; Rai, Tatemitsu; Uchida, Shinichi.

In: Journal of the American Society of Nephrology, Vol. 26, No. 7, 01.07.2015, p. 1525-1536.

Research output: Contribution to journalArticle

Kikuchi, E, Mori, T, Zeniya, M, Isobe, K, Ishigami-Yuasa, M, Fujii, S, Kagechika, H, Ishihara, T, Mizushima, T, Sasaki, S, Sohara, E, Rai, T & Uchida, S 2015, 'Discovery of novel SPAK inhibitors that block WNK kinase signaling to cation chloride transporters', Journal of the American Society of Nephrology, vol. 26, no. 7, pp. 1525-1536. https://doi.org/10.1681/ASN.2014060560
Kikuchi, Eriko ; Mori, Takayasu ; Zeniya, Moko ; Isobe, Kiyoshi ; Ishigami-Yuasa, Mari ; Fujii, Shinya ; Kagechika, Hiroyuki ; Ishihara, Tomoaki ; Mizushima, Tohru ; Sasaki, Sei ; Sohara, Eisei ; Rai, Tatemitsu ; Uchida, Shinichi. / Discovery of novel SPAK inhibitors that block WNK kinase signaling to cation chloride transporters. In: Journal of the American Society of Nephrology. 2015 ; Vol. 26, No. 7. pp. 1525-1536.
@article{eac4b8eaad0d4d298c1459b79c4187f9,
title = "Discovery of novel SPAK inhibitors that block WNK kinase signaling to cation chloride transporters",
abstract = "Upon activation by with-no-lysine kinases, STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) phosphorylates and activates SLC12A transporters such as the Na+-Cl2 cotransporter (NCC) and Na+-K+-2Cl2 cotransporter type 1 (NKCC1) and type 2 (NKCC2); these transporters have important roles in regulating BP throughNaCl reabsorption and vasoconstriction. SPAK knockoutmice are viable and display hypotension with decreased activity (phosphorylation) of NCC and NKCC1 in the kidneys and aorta, respectively. Therefore, agents that inhibit SPAK activity could be a new class of antihypertensive drugs with dual actions (i.e., NaCl diuresis and vasodilation). In this study, we developed a new ELISA-based screening system to find novel SPAK inhibitors and screened .20,000 small-molecule compounds. Furthermore, we used a drug repositioning strategy to identify existing drugs that inhibit SPAK activity. As a result, we discovered one small-molecule compound (Stock 1S-14279) and an antiparasitic agent (Closantel) that inhibited SPAK-regulated phosphorylation and activationofNCCandNKCC1in vitro and inmice. Notably, these compounds had structural similarity and inhibited SPAK in an ATP-insensitivemanner.Wepropose that the two compounds found in this study may have great potential as novel antihypertensive drugs.",
author = "Eriko Kikuchi and Takayasu Mori and Moko Zeniya and Kiyoshi Isobe and Mari Ishigami-Yuasa and Shinya Fujii and Hiroyuki Kagechika and Tomoaki Ishihara and Tohru Mizushima and Sei Sasaki and Eisei Sohara and Tatemitsu Rai and Shinichi Uchida",
year = "2015",
month = "7",
day = "1",
doi = "10.1681/ASN.2014060560",
language = "English",
volume = "26",
pages = "1525--1536",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "7",

}

TY - JOUR

T1 - Discovery of novel SPAK inhibitors that block WNK kinase signaling to cation chloride transporters

AU - Kikuchi, Eriko

AU - Mori, Takayasu

AU - Zeniya, Moko

AU - Isobe, Kiyoshi

AU - Ishigami-Yuasa, Mari

AU - Fujii, Shinya

AU - Kagechika, Hiroyuki

AU - Ishihara, Tomoaki

AU - Mizushima, Tohru

AU - Sasaki, Sei

AU - Sohara, Eisei

AU - Rai, Tatemitsu

AU - Uchida, Shinichi

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Upon activation by with-no-lysine kinases, STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) phosphorylates and activates SLC12A transporters such as the Na+-Cl2 cotransporter (NCC) and Na+-K+-2Cl2 cotransporter type 1 (NKCC1) and type 2 (NKCC2); these transporters have important roles in regulating BP throughNaCl reabsorption and vasoconstriction. SPAK knockoutmice are viable and display hypotension with decreased activity (phosphorylation) of NCC and NKCC1 in the kidneys and aorta, respectively. Therefore, agents that inhibit SPAK activity could be a new class of antihypertensive drugs with dual actions (i.e., NaCl diuresis and vasodilation). In this study, we developed a new ELISA-based screening system to find novel SPAK inhibitors and screened .20,000 small-molecule compounds. Furthermore, we used a drug repositioning strategy to identify existing drugs that inhibit SPAK activity. As a result, we discovered one small-molecule compound (Stock 1S-14279) and an antiparasitic agent (Closantel) that inhibited SPAK-regulated phosphorylation and activationofNCCandNKCC1in vitro and inmice. Notably, these compounds had structural similarity and inhibited SPAK in an ATP-insensitivemanner.Wepropose that the two compounds found in this study may have great potential as novel antihypertensive drugs.

AB - Upon activation by with-no-lysine kinases, STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) phosphorylates and activates SLC12A transporters such as the Na+-Cl2 cotransporter (NCC) and Na+-K+-2Cl2 cotransporter type 1 (NKCC1) and type 2 (NKCC2); these transporters have important roles in regulating BP throughNaCl reabsorption and vasoconstriction. SPAK knockoutmice are viable and display hypotension with decreased activity (phosphorylation) of NCC and NKCC1 in the kidneys and aorta, respectively. Therefore, agents that inhibit SPAK activity could be a new class of antihypertensive drugs with dual actions (i.e., NaCl diuresis and vasodilation). In this study, we developed a new ELISA-based screening system to find novel SPAK inhibitors and screened .20,000 small-molecule compounds. Furthermore, we used a drug repositioning strategy to identify existing drugs that inhibit SPAK activity. As a result, we discovered one small-molecule compound (Stock 1S-14279) and an antiparasitic agent (Closantel) that inhibited SPAK-regulated phosphorylation and activationofNCCandNKCC1in vitro and inmice. Notably, these compounds had structural similarity and inhibited SPAK in an ATP-insensitivemanner.Wepropose that the two compounds found in this study may have great potential as novel antihypertensive drugs.

UR - http://www.scopus.com/inward/record.url?scp=84934766234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934766234&partnerID=8YFLogxK

U2 - 10.1681/ASN.2014060560

DO - 10.1681/ASN.2014060560

M3 - Article

AN - SCOPUS:84934766234

VL - 26

SP - 1525

EP - 1536

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 7

ER -